ReviewInfection2021
Deciphering the epidemiology of invasive candidiasis in the intensive care unit: is it possible?
Review in Infection, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Candidemia Following Severe COVID-19 in Hospitalised and Critical Ill Patients: A Systematic Review and Meta-Analysis.Mycoses · 2024Pooled it
- Therapeutic potential of traditional Chinese medicine-derived formulations and extracts inJournal of pharmaceutical analysis · 2026Review
- Observational
- Invasive Candidiasis in Critically Ill Patients: Fundamental Concepts and Future Directions.Chest · 2026Review
- Article
- Propofol decreases the resistance of neutrophils to Candida albicans by inhibiting ferroptosis and the cGAS-STING pathway.American journal of translational research · 2026Article
- French intensive care physicians' practices for the management of high-risk patients with invasive candidiasis: results from the multicenter INSPIRE survey.Annals of intensive care · 2026Article
- Proteomics and β-hydroxybutyrylome reveal the novel mechanisms underlying fluconazole resistance inFuture microbiology · 2025Article
- Early-Onset Candidemia in Adult Intensive Care Units.Diagnostics (Basel, Switzerland) · 2025Review
- Improved Sixty-Day Mortality in Candidemia with Antifungal Treatment Within 72 Hours of Fever Onset: A Single-Center Retrospective Study in Rural Japan.Infectious disease reports · 2025Article
- Synthesis and Evaluation of a Chitosan-Based Cationic Hydrogel with Strong Antifungal and Antibiofilm Activities Against Clinical Isolates ofPharmaceuticals (Basel, Switzerland) · 2025Article
- External Validation of Risk Prediction Score for Candidemia in Critically Ill Patients: A Retrospective Observational Study.Journal of fungi (Basel, Switzerland) · 2025Article
- Optimization ofFrontiers in bioengineering and biotechnology · 2025Article
- Epidemiological shifts and advances in research on early diagnosis of invasive fungal infection in critically ill patients.Frontiers in cellular and infection microbiology · 2025Review
- Isolation ofJournal of fungi (Basel, Switzerland) · 2024Article
- Insights intoJournal of fungi (Basel, Switzerland) · 2024Article
- UPLC-MS/MS method for fluconazole determination in plasma and its application in Mexican patients with candidaemia.Bioanalysis · 2024Article
- Candida albicans and Antifungal Peptides.Infectious diseases and therapy · 2023Article
- Pharmacokinetic and pharmacodynamic considerations for antifungal therapy optimisation in the treatment of intra-abdominal candidiasis.Critical care (London, England) · 2023Review
- Trends in antifungal resistance inAntimicrobial agents and chemotherapy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive candidiasis (IC) has emerged in the last decades as an important cause of morbidity, mortality, and economic load in the intensive care unit (ICU). The epidemiology of IC is still a difficult and unsolved enigma for the literature. Accurate estimation of the true burden of IC is difficult due to variation in definitions and limitations inherent to available case-finding methodologies. Candidemia and intra-abdominal candidiasis (IAC) are the two predominant types of IC in ICU. During the last two decades, an increase in the incidence of candidemia has been constantly reported particularly in the expanding populations of elderly or immunosuppressed patents, with a parallel change in Candida species (spp.) distribution worldwide. Epidemiological shift in non-albicans spp. has reached worrisome trends. Recently, a novel, multidrug-resistant Candida spp., Candida auris, has globally emerged as a nosocomial pathogen causing a broad range of healthcare-associated invasive infections. Epidemiological profile of IAC remains imprecise. Though antifungal drugs are available for Candida infections, mortality rates continue to be high, estimated to be up to 50%. Increased use of fluconazole and echinocandins has been associated with the emergence of resistance to these drugs, which affects particularly C. albicans and C. glabrata. Crucial priorities for clinicians are to recognize the epidemiological trends of IC as well as the emergence of resistance to antifungal agents to improve diagnostic techniques and strategies, develop international surveillance networks and antifungal stewardship programmes for a better epidemiological control of IC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.